Additionally, evaluation of preclinical studies did not note a clear trend for efficacy based on immunotherapeutic agent alone ( Figure 3 ), which suggests that other factors (timing, frequency, delivery medium) also strongly impact treatment outcome.
← all excerpts
Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.
1
—
—